Antisense and RNAi Therapeutics Market Research Report 2024: Global Market to Reach $3.6 Billion by 2030 - Investments in RNA-Based Research Expands the Market for Novel Therapeutic Approaches
November 19, 2024 10:53 ET
|
Research and Markets
Dublin, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The "Antisense and RNAi Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
North America RNA Therapeutics Market Research 2024-2029: Revolutionary Advancements in RNA Technology and Personalized Medicine Propel Growth
November 14, 2024 05:21 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Antisense & RNAi Therapeutics Market Overview 2024-2030 - Global Antisense & RNAi Therapeutics Market Forecast to Reach $14.4 Billion by 2030
November 12, 2024 05:33 ET
|
Research and Markets
Dublin, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The "Antisense & RNAi Therapeutics - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global market for...
e-therapeutics Announces Business Updates and Interim Results
October 31, 2024 09:00 ET
|
e-therapeutics plc
LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
September 17, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
RNAi Market and Technologies Industry Report 2024, with Company Profiles of Major Players including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
August 23, 2024 04:02 ET
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "RNAi Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for RNAi technology is estimated to...
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
July 30, 2024 09:05 ET
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
June 12, 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
Phio Pharmaceuticals Secures New Investor
May 17, 2024 09:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
May 16, 2024 08:00 ET
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...